Feiyan Wang

Dr. Feiyan Wang


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 March 2026 in International Journal of Biological Macromolecules
Verified
Journal Article
Closed access
JZJiawei Zhang
Jiawei Zhang
ZXZhenfang Xu
Zhenfang Xu
SLShuangshuang Liu
Shuangshuang Liu
XWXiwei Wang
Xiwei Wang
FWFeiyan Wang
Feiyan Wang
LXLiang Xu
Liang Xu

7 December 2025 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
XMXueling Ma
Xueling Ma
SLShuangshuang Liu
Shuangshuang Liu
XDXiao Dong
Xiao Dong
XLXiuhua Li
Xiuhua Li
FWFeiyan Wang
Feiyan Wang
LXLiang Xu
Liang Xu
Background: High expression of nucleolin (NCL) on the surface of tumor cells is closely associated with disease progression and poor prognosis. The aptamer–PROTAC conjugate (APC) technology provides a novel molecular design strategy for the targeted degradation of NCL. Methods: Based on the principles of PROTAC technology and chemical modification techniques, in this study, a series of AS1411-lenalidomide chimeras featuring different linker structures were designed and synthesized for the specific purpose of targeted degradation of NCL. Four AS1411-PROTACs (C1–C4) were successfully constructed via a click chemistry strategy, and their structures were validated. Results: In vitro experimental results showed that C4 exhibited the most optimal activity, significantly downregulating NCL expression and inhibiting the proliferation of breast cancer cells (MCF-7). Notably, the activity of C4 remained unaltered regardless of the annealing process. Mechanistic studies demonstrated that C4 induced NCL degradation through the ubiquitin–proteasome pathway while also promoting apoptosis and cell cycle arrest. In a nude mouse tumor model, C4 displayed potent antitumor efficacy, with no discernible signs of obvious systemic toxicity. Conclusions: This study provides compelling evidence demonstrating that C4 is a highly promising anticancer compound. It also provides important evidence for the development of novel nucleic acid aptamer–PROTAC conjugate drugs for more clinical applications.